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The effect of wortmannin on IgG-receptor (FccR)-mediated
stimulation of human neutrophils was investigated. The Ca#+
influx induced by clustering of both Fcc receptors was inhibited
by wortmannin, as was the release of Ca#+ from intracellular
stores. Wortmannin also inhibited, with the same efficacy, the
accumulation of Ins(1,4,5)P
$
observed after FccR stimulation,
but did not affect the increase in Ins(1,4,5)P
$
induced by the
chemotactic peptide, formyl-methionine-leucine-phenylalanine.
Because wortmannin is, in the concentrations used here, an
inhibitor of PtdIns 3-kinase, these results suggested a role for
PtdIns 3-kinase upstream of Ca#+ signalling, induced by FccR
cross-linking. Support for this notion was obtained by investi-
gating the effect of another inhibitor of PtdIns 3-kinase, LY
INTRODUCTION
Human neutrophils possess two types of receptor for IgG (FccR),
FccRIIa and FccRIIIb. Each of these receptors induces neutro-
phil activation after cross-linking. One of the earliest signalling
events that is observed is an increase in the intracellular Ca#+
concentration ([Ca#+]
i
). We have shown that although separate
FccR cross-linking induces release of Ca#+ from intracellular
stores, cross-linking of both receptors together in a heterotypic
complex induces a synergistic Ca#+ response, mainly due to an
effective stimulation of Ca#+ influx from the extracellular medium
[1]. As yet, the exact mechanism of neutrophil activation via
heterotypic FccR cross-linking remains to be determined.
FccRIIIb is linked to the membrane via a glycan–phos-
phatidylinositol (GPI) anchor. FccRIIa is a transmembrane
receptor containing an immune receptor tyrosine-based acti-
vation motif (known as the ITAM or Reth motif) [2] (E-X
)
-D-
X-X-Y-X-X-L-X
"#
-Y-X-X-L) in the cytoplasmic tail, which has
been shown to be involved in signalling of FccRIIa [3,4]. This
signalling motif is found also in subunits of the T- and B-cell
antigen receptor complexes [5]. Association of FccRIIa from
neutrophils with the src-like kinase Fgr has been described [6]. It
is not clear how the GPI-anchored FccRIIIb, without a tran-
smembrane and cytoplasmic tail, transduces signals through the
membrane. It has been suggested that other GPI-anchored
molecules use src-like kinases for signalling [7]. The mechanism
of association between these proteins is probably mediated via
Abbreviations used: bsAb, bispecific antibody; FccR, the receptors for IgG; GAM, goat anti-mouse; PtdIns 3-kinase, 1-phosphatidylinositol 3-kinase ;
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294002, and by studying the kinetics of PtdIns 3-kinase activation.
We found translocation of PtdIns 3-kinase to the plasma
membrane and increased PtdIns 3-kinase activity in the mem-
brane as soon as 5 s after FccR cross-linking, even before the
onset of the Ca#+ response. Moreover, the translocation of
PtdIns 3-kinase to the plasma membrane was inhibited by co-
cross-linking of either FccRIIa and FccRIIIb with the tyrosine
phosphatase, CD45, indicating a requirement for protein tyrosine
phosphorylation in the recruitment of PtdIns 3-kinase to the
plasma membrane. Taken together, our results suggest a role for
PtdIns 3-kinase in early signal transduction events after FccR
cross-linking in human neutrophils.
lipid–lipid interactions involving the lipid anchor of the receptor
and the myristoylation and palmitoylation of the src-like
kinase [8].
The lipid kinase, PtdIns 3-kinase, which has been found in
many activated receptor complexes [9,10], phosphorylates PtdIns,
PtdIns4P and PtdIns(4,5)P
#
to form PtdIns3P, PtdIns(3,4)P
#
and
PtdIns(3,4,5)P
$
respectively. It has been suggested that these
lipids act as second messengers [11], but their functions are not
yet clear. PtdIns 3-kinase is a heterodimeric protein containing
an 85 kDa regulatory subunit (p85) and a 110 kDa catalytic
subunit (p110) [12]. The p85 subunit contains an SH2 domain
that can bind to tyrosine-phosphorylated proteins in the mem-
brane, inducing activation of the enzyme [13], e.g. during T-cell
receptor activation to the phosphorylated immune receptor
tyrosine-based activation motif of CD3f [14]. Recently, a role for
PtdIns 3-kinase in FccR-induced signalling has been suggested.
In guinea pig neutrophils, antibody-dependent cellular cyto-
toxicity is inhibited by wortmannin, an inhibitor that appears to
be specific for PtdIns 3-kinase in the nanomolar range [15–18].
Triggering of either FccRI or FccRII in U937 cells induces
increased PtdIns 3-kinase activity [19].
The results of our study suggest the involvement of PtdIns 3-
kinase in FccR-induced Ca#+ signalling in human neutrophils.
To investigate the relevance of tyrosine phosphorylation in this
process, we have studied the effect of bringing CD45, a memb-
rane-bound protein tyrosine phosphatase [20], which is highly
expressed on neutrophils, in close proximity to the FccR.
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MATERIALS AND METHODS
Materials
Wortmannin, formyl-methionine-leucine-phenylalanine (fMLP)
and streptavidin were from Sigma Chemical Co. (St. Louis,
MO, U.S.A.), ionomycin from Calbiochem (La Jolla, CA,
U.S.A.) and indo-1}AM from Molecular Probes (Eugene, OR,
U.S.A.). LY 294002 was from Biomol (Plymouth Meeting,
PA, U.S.A.). Wortmannin was dissolved in DMSO at a conc-
entration of 100 lM. LY 294002 was dissolved in DMSO at a
concentration of 80 mM. F(ab«)
#
fragments of polyclonal goat
anti-mouse (GAM) IgG, Fcc fragment specific [GAM-Fc F(ab«)
#
]
and F(ab«)
#
fragments of polyclonal GAM IgG [GAM F(ab«)
#
]
were purchased from Jackson Immunoresearch Laboratories,
Inc. (West Grove, PA, U.S.A.). The incubation medium con-
tained 132 mM NaCl}6 mM KCl}1 mM CaCl
#
}1 mM
MgSO
%
}1.2 mM potassium phosphate}20 mM Hepes}5.5 mM
glucose}0.5% (w}v) human serum albumin, pH 7.4.
Isolation of neutrophils
Neutrophils from blood obtained from healthy individuals were
isolated by Percoll density gradient centrifugation and isotonic
lysis of contaminating erythrocytes as described previously [1].
Antibodies
The anti-FccRIII monoclonal antibodies (mAbs) were 3G8
(mIgG1) [21] and CLBFcgran1 (mIgG2a) [22]. CLBFcgran 1 was
used in all experiments except for the control responses for the
bispecific antibody (bsAb). The anti-(human FccRII) mAb IV.3
(mIgG2b) [23] was used. As CD45 antibody, mAb 3D3 (mIgG1)
was used [R. A. W. van Lier, Central Laboratory of the
Netherland’s Red Cross Blood Transfusion Service (CLB),
Amsterdam, The Netherlands]. W6}32 mAb, directed against
HLA class I, was used as a control antibody. The mAbs were
purified from hybridoma culture supernatant by precipitation
with 50% saturated ammonium sulphate and subsequent Protein
A affinity chromatography. Fab fragments were prepared by
digestion with 4% (w}v) papain in PBS containing 5 mM EDTA
and 10 mM cysteine, for 90 min at 37 °C. The reaction was
terminated by adding 20 mM iodoacetamide. F(ab«)
#
fragments
were prepared by digestion with 2% (w}v) pepsin, pH 3.7, for
16 h at 37 °C. Fc parts were removed by Protein A affinity-
chromatography. Antibodies were biotinylated with N-hydroxy-
succinimide-LC-biotin (250 lg}ml) (Pierce, Rockfort, IL,
U.S.A.) for 4 h at room temperature. Free biotin was removed
by dialysis against PBS.
Cell activation
Heterotypic FccR cross-linking was performed by preincubation
of the cells with biotinylated Fab fragments of anti-FccRII and
anti-FccRIII mAbs (5 lg}ml each) for 5 min at 37 °C. Cells were
washed and resuspended in incubation medium, prewarmed to
37 °C. The cells were incubated for 5 min at 37 °C in the absence
or presence of wortmannin or LY 294002. Cross-linking of
biotinylated antibodies was performed by adding streptavidin
(1.5 lg}ml or 10 lg}ml, as specified in the Figure legends), with
stirring. Co-cross-linking of FccRs with CD45 was performed by
preincubation of the cells with biotinylated F(ab«)
#
fragments of
CD45 (5 lg}ml) for 5 min at 37 °C. Subsequently, biotinylated
Fab fragments of anti-FccRII (5 lg}ml) or anti-FccRIII mAb
(5 lg}ml) or both together were added. After 5 min at 37 °C,
cells were washed and resuspended in incubation medium that
had been prewarmed to 37 °C. Cross-linking was performed with
streptavidin (10 lg}ml) with stirring. Alternatively, neutrophils
were pretreated for 5 min at 37 °C with a bsAb (see below)
directed against FccRIII and CD45 (20 lg}ml) or with anti-
FccRIII Fab fragments (10 lg}ml). Cross-linking was performed
with GAM F(ab«)
#
fragments (50 lg}ml).
Preparation of bispecific antibody
The bsAb directed against FccRIII and CD45 was prepared by
chemical cross-linking. 3G8 mAb and 3D3 mAb were digested
by pepsin to F(ab«)
#
fragments. 3G8 F(ab«)
#
and 3D3 F(ab«)
#
were reduced with 15 mM 2-mercaptoethanol in PBS}2 mM
EDTA for 30 min at 30 °C to obtain Fab«SH fragments. Excess
2-mercaptoethanol was removed by gel filtration in a Sephadex-
G25 column equilibrated with PBS}2 mM EDTA, pH 6.7.
3G8 Fab«SH was incubated with a 40¬molar excess of
bis-maleimidohexane (Pierce) for 60 min at 30 °C. Free bis-
maleimidohexane was removed by gel filtration in a Sephadex-
G25 column equilibrated with PBS}2 mM EDTA, pH 6.7.
3G8 Fab–bis-maleimidohexane and 3D3 Fab«SH were concen-
trated to approx. 5 mg}ml in C30 Amicon concentration units
(Amicon, Beverly, MA, U.S.A.) and were incubated together for
16 h at room temperature. The yield of bsAb using this procedure
was about 30%. The bsAb was separated from the remaining
Fab fragments by gel filtration by FPLC in a Superose 12 column
equilibrated with PBS.
Characterization of the bsAb, FccRIII¬CD45
Binding of the bsAb to various cells was analysed by indirect
immunofluorescence and flow cytometry (FACScan, Becton
Dickinson, San Jose, CA, U.S.A.). As expected, the bsAb,
FccRIII¬CD45, showed a high degree of binding to neutrophils
(results not shown). The bsAb also showed binding to the EBV-
transformed B-cell line, JY, which expresses CD45 but lacks
FccRIII : a mean fluorescence intensity of 566³59 was obtained,
compared with 67³6 with the anti-FccRIII F(ab«)
#
, 517³55
with CD45 F(ab«)
#
and 61³5 with the isotype-matched control
(means³S.E.M. of three experiments). In addition, the bsAb
showed binding to CHOFccRIIIb cells that were transfected with
FccRIIIb [24] but expressed no CD45; a mean fluorescence
intensity of 737³71 was obtained compared with 552³69 with
anti-FccRIII F(ab«)
#
, 98³7 with anti-CD45 F(ab«)
#
and 93³4
with the isotype-matched control (means³S.E.M. of three
experiments). Untransfected CHOwt cells did not bind the bsAb.
These experiments showed that both antigen recognition sites
were present in the bsAb, FccRIII¬CD45.
Measurements of the cytosolic free Ca2+ concentration ([Ca2+]i)
Determination of [Ca#+]
i
was performed as described previously
[1]. In experiments carried out in the presence of EGTA, cells
were preincubated with biotinylated antibodies in normal in-
cubation medium, washed and resuspended at a concentration of
2¬10' cells}ml in medium without Ca#+. Just before cross-
linking, 1 mM EGTA was added. Assessment of Ca#+ influx was
carried out using the Mn#+ quenching technique, as described
previously [1].
Measurement of Ins(1,4,5)P3 levels
Ins(1,4,5)P
$
was assayed using a system from Amersham In-
ternational. Neutrophils (1¬10( cells}ml in incubation medium)
were preincubated with biotinylated anti-FccR Fab fragments
89FccR-induced Ca2+ signalling involves phosphatidylinositol 3-kinase
for 5 min, washed and resuspended in PBS [Ins(1,4,5)P
$
levels
could not be measured reliably when incubation medium was
used, probably due to breakdown after disruption of the cells].
At various times after stimulation of the cells with streptavidin,
300 ll of each sample was added to 150 ll of 50 mM Tris}HCl
(pH 8.0) containing 4 mM EDTA, frozen immediately in liquid
N
#
and stored at ®80 °C. After thawing, the samples were
centrifuged in the cold for 5 min at 10000 g. Ins(1,4,5)P
$
was
assessed by measuring the competition between unlabelled
Ins(1,4,5)P
$
, present in the samples, and a fixed amount of
[$H]Ins(1,4,5)P
$
for a limited number of binding sites on an
Ins(1,4,5)P
$
-binding protein preparation. The amount of
Ins(1,4,5)P
$
was determined by intrapolation from a standard
curve obtained with known quantities of unlabelled Ins(1,4,5)P
$
.
Detection of PtdIns 3-kinase translocation
Fractionation of membranes and cytosol from neutrophils was
performed as described previously [25]. Neutrophils (1¬10(
cells}ml in incubation medium) were preincubated for 5 min at
37 °C with biotinylated Fab fragments of anti-FccRII mAb and
anti-FccRIII mAb. The cells were washed and resuspended in
incubation medium at 37 °C and were transferred to a stirred
cuvette maintained at 37 °C. Cross-linking was performed by the
addition of streptavidin. At different time points, stimulation
was stopped by the addition of a 5¬ excess of ice-cold PBS. The
neutrophils were centrifuged and resuspended (8¬10( cells}ml)
in ice-cold sonication buffer [10 mM Hepes, pH 7.2}1 mM
EGTA}5% (w}v) sucrose, containing a protease inhibitor cock-
tail (Complete4, Boehringer, Mannheim, Germany)]. After soni-
cation of the neutrophil suspension (3¬15 s at 21 kHz frequency
and 8 lm peak-to-peak amplitude), 1 ml of postnuclear super-
natant was layered on to a discontinuous sucrose gradient,
consisting of 1 ml of 52% (w}v) sucrose, 1 ml of 40% (w}v)
sucrose and 1 ml of 15% (w}v) sucrose. After centrifugation
(100000 g, for 35 min at 4 °C), 80% of the supernatant (cytosol)
and the interface between the 15% and 40% sucrose layers
(plasma membranes) were collected. Membrane fractions were
treated with ice-cold trichloroacetic acid (10%, w}v) for 15 min.
After centrifugation (12000 g, for 15 min at 4 °C), pellets were
taken up in Laemmli sample buffer [125 mM Tris}HCl, pH 6.8
containing 8% (w}v) SDS, 10% (v}v) 2-mercaptoethanol and
10% (v}v) glycerol] and were boiled for 5 min. The presence of
PtdIns 3-kinase in the cytosol fraction (derived from 8¬10& cells)
and the plasma membrane fraction (derived from 4¬10( cells)
was determined by SDS}PAGE and immunoblotting with a
polyclonal rabbit antibody directed against the 85-kDa subunit
(p85) of PtdIns 3-kinase (Affinity, Nottingham, U.K.). For
detection of the primary antibody, the blots were incubated with
horse anti-rabbit immunoglobulin antibodies conjugated to
horseradish peroxidase (CLB, Amsterdam, The Netherlands)
and were developed using enhanced chemiluminescence (Boeh-
ringer). The proteins were visualized by exposure to a KODAK
X-OMAT S film for 1 min.
Measurement of PtdIns 3-kinase activity
An equal volume of lysis buffer [6% (v}v) Nonidet P-40, 40 mM
Tris}HCl, pH 8.0, 200 mM NaCl, 20 mM Na
$
P
#
O
(
, 4 mM
EDTA, 100 mM NaF, 2 mM Na
$
VO
%
, 2 mM PMSF, 200 lM
leupeptin, 8 lg}ml soybean trypsin inhibitor, 20 lg}ml aprotinin]
was added to the neutrophil membrane and cytosol fractions
(25¬10' cell and 12.5¬10' cell equivalents per immunoprecip-
itation respectively). A lysate of rat-1 fibroblasts served as a
positive control for the measurement of PtdIns 3-kinase activity.
Lysates were immunoprecipitated for 1 h at 4 °C with anti-p85
polyclonal rabbit antiserum (UBI, Lake Placid, NY, U.S.A.) or
normal rabbit serum (1.7 ll per sample). Protein A–Sepharose
(Sigma) was added before incubation overnight at 4 °C. The
Protein A–Sepharose beads were washed four times with half-
strength lysis buffer and twice with 10 mM Tris}HCl, pH 7.4,
containing 1 mM Na
$
VO
%
. PtdIns 3-kinase activity was measured
by adding 100 lg of sonicated PtdIns (Sigma) and 10 lCi of [c-
$#P]ATP in the presence of 200 lM adenosine, 30 mM MgCl
#
and 40 mM ATP in a volume of 60 ll. The reactions were carried
out for 20 min at room temperature and were stopped by the
addition of 100 ll of 1 M HCl and 200 ll of chloroform}
methanol (1 :1, v}v). After centrifugation and removal of the
upper layer, 80 ll of methanol}HCl was added and the mixture
was again centrifuged. The lipids were separated on TLC plates
(Merck) using a solvent system of chloroform}methanol}N-
H
%
OH (45:35:10, by vol.). The TLC plates were exposed to X-
ray film at ®80 °C.
Western blot analysis for phosphotyrosine
Neutrophils were suspended in incubation medium (as described
above) without human serum albumin. The cells (10( cells}ml)
were preincubated at 37 °C with biotinylated mAb as indicated
in the text, washed and resuspended at 10( cells}ml. At various
times after the addition of streptavidin, 50 ll of cell suspension
was mixed with 50 ll of sample buffer [125 mM Tris}HCl,
pH 6.8, 4% (w}v) SDS, 10% (v}v) 2-mercaptoethanol and 10%
(v}v) glycerol] containing 1 mM Na
$
VO
%
, preheated to 100 °C
and maintained at 100 °C for 10 min. The samples were analysed
after SDS}PAGE by immunoblotting with monoclonal anti-
phosphotyrosine antibody (UBI). The amount of anti-phos-
photyrosine bound to the blot was determined with peroxidase-
labelled horse anti-mouse Ig and enhanced chemilumin-
escence.To verify equal loading of protein in each lane, blots
were subsequently incubated with a rabbit antiserum directed
against the C-terminus of p47-phox [25], which was detected by
peroxidase-labelled horse anti-rabbit Ig antibodies (CLB,
Amsterdam, The Netherlands).
Statistical analysis
For statistical analysis, paired Student’s t-tests were performed.
P values exceeding 0.05 were considered not significant.
RESULTS
Effect of wortmannin on FccR-induced Ca2+ responses
In a previous study we observed that the heterotypic clustering of
both FccRs on human neutrophils primarily induces Ca#+ influx
from the extracellular medium [1]. To obtain more insight into
the signalling pathways involved, we investigated the effect of
wortmannin. Wortmannin has been shown to interfere with a
protein kinase C-independent pathway necessary for fMLP-
induced superoxide production [26] and has subsequently been
shown to inhibit the activity of PtdIns 3-kinase [15,17]. Ca#+
influx induced by cross-linking of both FccRIIa and FccRIIIb,
as measured by Mn#+ influx, was completely inhibited by 100 nM
wortmannin (Figure 1, upper panel).
In neutrophils, the capacitive Ca#+ entry model, in which
depletion of the Ca#+ stores generates a signal that induces Ca#+
influx from the extracellular medium, seems applicable [27,28].
To investigate whether the site of action of wortmannin was
upstream or downstream of the mobilization of Ca#+ from the
stores, FccR cross-linking was performed in the presence of
EGTA to prevent Ca#+ influx. Under these conditions, the
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Figure 1 Effect of wortmannin on Ca2+ influx and intracellular Ca2+
mobilization induced as a result of heterotypic FccR cross-linking
Indo-1-loaded neutrophils preincubated with biotinylated Fab fragments of anti-FccR mAb were
resuspended in incubation medium (upper panel) with 0.2 mM Ca2+ or medium without Ca2+
(lower panel). Cells were treated with or without (control) 100 nM wortmannin. For measurement
of Ca2+ influx (upper panel), 0.5 mM MnCl2 was added 2 min before the addition of streptavidin
(10 lg/ml, first arrow). To completely quench Mn2+-induced indo-1 fluorescence, digitonin
(10 lM) was added (second arrow). The results shown are representative of three experiments.
For measurement of Ca2+ mobilization (lower panel), 1 mM EGTA (first arrow) was added 30 s
before the addition of streptavidin (10 lg/ml, second arrow). The mean change in peak values
of [Ca2+]i were (means³S.E.M., n ¯ 4) 644³116 nM in the absence of wortmannin and
112³20 nM in the presence of 100 nM wortmannin. The Ca2+ concentration in resting cells
was 60³2 nM.
Ca#+ response induced by heterotypic FccR cross-linking was
also inhibited by wortmannin (Figure 1, lower panel). Half-
maximal inhibition was observed at a concentration of approx-
imately 25 nM wortmannin (results not shown).
Effect of wortmannin on FccR-induced Ins(1,4,5)P3 accumulation
Under our experimental conditions, the heterotypic cross-linking
of FccR released Ca#+ from intracellular stores. This probably
results from the generation of Ins(1,4,5)P
$
[29]. Measurements of
the levels of Ins(1,4,5)P
$
indeed showed a clear increase upon
heterotypic FccR cross-linking (Figure 2A), suggesting that the
Ca#+ response is (at least in part) mediated by a rise in InsP
$
. The
increase in the Ins(1,4,5)P
$
accumulation after FccR cross-
linking was also inhibited by wortmannin (Figure 2A). For
comparison, the fMLP-induced generation of Ins(1,4,5)P
$
was
also measured in these experiments and found to be unaffected
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Figure 2 Effect of wortmannin on the Ins(1,4,5)P3 accumulation induced
after (A) heterotypic FccR cross-linking or (B) fMLP stimulation
(A) Neutrophils (PMN) were preincubated with biotinylated Fab fragments of anti-FccR mAb.
The cells were incubated with (+) or without (*) 100 nM wortmannin ; cross-linking was
performed by the addition of 1.5 lg/ml streptavidin. Samples for Ins(1,4,5)P3 (IP3) measurement
were taken at different time points as described in the Materials and methods section. (B) For
comparison, untreated cells were incubated with (E) or without (D) 100 nM wortmannin and
stimulated with 1 lM fMLP. At the time-points marked with an asterisk, wortmannin inhibited
the Ins(1,4,5)P3 (IP3) accumulation significantly (P !0.05). Values are the means³S.E.M. of
three independent experiments.
by wortmannin (Figure 2B). This latter finding is in accordance
with previous data showing that the Ca#+ response evoked by
fMLP is not sensitive to wortmannin [26]. The difference in
sensitivity to wortmannin is not due to the different amounts of
Ins(1,4,5)P
$
accumulation. Higher concentrations of streptavidin
(10 lg}ml) induced an increase in the accumulation of
Ins(1,4,5)P
$
of 3.24³0.92 pmol}10' cells at 20 s after stimulation.
In the presence of wortmannin, this accumulation was inhibited
by 95% (to 0.14³0.16 pmol}10' cells).
The IC
&!
value for the wortmannin inhibition of Ins(1,4,5)P
$
accumulation after FccR cross-linking (under conditions of
cross-linking with 10 lg}ml streptavidin) was approx. 25 nM
(results not shown), which is comparable with the wortmannin
concentration needed for inhibition of the Ca#+ response under
these conditions. In addition, the accumulation of Ins(1,4,5)P
$
upon heterotypic FccR cross-linking was also inhibited by
another inhibitor of PtdIns 3-kinase, LY 294002 [30]. The IC
&!
for LY 294002 was approx. 1.5 lM (results not shown).
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Figure 3 Effect of heterotypic FccR cross-linking on the localization of
PtdIns 3-kinase
Neutrophils preincubated with biotinylated Fab fragments of anti-FccR mAb were activated by
addition of 1.5 lg/ml streptavidin. Under resting conditions, no streptavidin was added. At
different time points neutrophils were fractionated as described in the Materials and methods
section. Immunoblotting with membrane and cytosol fractions was performed with an antibody
directed against the p85 subunit of PtdIns 3-kinase. This Figure is representative of three
independent experiments. Molecular-mass markers (kDa) are shown on the left.
Figure 4 Effect of heterotypic FccR cross-linking on the activation of
PtdIns 3-kinase
Neutrophils were preincubated with biotinylated Fab fragments of anti-FccR mAb and activation
by addition of 1.5 lg/ml (lanes 2 and 6) or 10 lg/ml (lanes 3 and 7) streptavidin. Under
resting conditions, no streptavidin was added (lanes 1 and 5). After 5 s stimulation, samples
were taken as described in the Materials and methods section. Immunoprecipitations of p85
(all lanes except lane 4) or normal rabbit serum (lane 4) from membrane and cytosol fractions
were assayed for kinase activity towards PtdIns. The location of PtdIns3P (PIP) in the
chromatogram was confirmed by comparison with PtdIns3P generated enzymically by
immunoprecipitation of p85 from Rat-1 fibroblasts. This Figure is representative of three
independent experiments.
Localization and activity of PtdIns 3-kinase
Because early signalling events after FccR cross-linking appeared
sensitive to wortmannin and LY 294002, we investigated the
possibility that PtdIns 3-kinase is activated very early after Fcc
receptor activation in human neutrophils. We observed an
increased amount of the p85 subunit of PtdIns 3-kinase in the
membrane after only 5 s (Figure 3), before any increase in
Ins(1,4,5)P
$
was observed under these suboptimal conditions of
cross-linking (Figure 2A). Neither biotinylated Fab fragments of
anti-FccR mAb nor streptavidin alone induced translocation of
p85 to the membrane (results not shown). We did not always
observe a clear decrease in the amount of p85 in the cytosol
fraction, probably due to the relatively small amount of PtdIns
Table 1 Effect of CD45 co-cross-linking on the FccR-induced increase in
[Ca2+]i in human neutrophils
Indo-1-loaded neutrophils were preincubated with the indicated antibodies as described in the
Materials and methods section. The peak increase in [Ca2+]i after cross-linking represents the
means³S.E.M. of 3–4 experiments. [Ca2+]i in resting cells amounted to 62³1 nM (n ¯ 36).
*Significantly different from control response (P ! 0.05).
Increase in
Treatment [Ca2+]i (nM)
Anti-FccRII biotinylated Fab­streptavidin 709³102
Anti-FccRII­CD45 biotinylated F(ab«)2­streptavidin 7³7
Anti-FccRIII biotinylated Fab­streptavidin 511³102
Anti-FccRIII­CD45 biotinylated F(ab«)2­streptavidin 99³30*
Anti-FccRII biotinylated Fab­anti-FccRIII biotinylated Fab­streptavidin 2646³416
Anti-FccRII biotinylated Fab­anti-FccRIII biotinylated Fab ­CD45
biotinylated F(ab«)2­streptavidin
1202³119*
Anti-FccRIII Fab­GAM F(ab«)2 116³47*
BsAb FccRIII¬CD45­GAM F(ab«)2 10³1*
CD45 F(ab«)2­anti-FccRIII Fab­GAM F(ab«)2 2³2*
3-kinase translocating to the membrane. The Ca#+ ionophore,
ionomycin, did not induce translocation of p85 to the membrane
(results not shown) indicating that the FccR-induced trans-
location was not the consequence of the Ca#+ elevation observed.
To establish that the p85 subunit of PtdIns 3-kinase recovered
in the membrane fraction was part of an active enzyme complex,
the activity of PtdIns 3-kinase was measured in membrane and
cytosol fractions after FccR cross-linking. Increased PtdIns 3-
kinase activity in the membrane was observed after 5 s of
heterotypic FccR cross-linking (Figure 4). Even under conditions
of suboptimal cross-linking using 1.5 lg}ml streptavidin, before
any increase in Ins(1,4,5)P
$
accumulation was detected (Figure
2A), an increased PtdIns 3-kinase activity was observed. In
addition, a decrease in PtdIns 3-kinase activity was found in the
cytosol after FccR cross-linking.
Inhibition of the FccR-induced tyrosine phosphorylation and
translocation of PtdIns 3-kinase by CD45
In order to investigate the role of tyrosine phosphorylation in the
FccR-induced translocation of PtdIns 3-kinase in human neut-
rophils, the protein tyrosine phosphatase, CD45, was co-cross-
linked with FccRs. As observed by Hoffmeyer et al. [31], co-
cross-linking of CD45 with FccRIIIb or FccRIIa strongly
inhibited the FccR-mediated Ca#+ response (Table 1). The
inhibitory effects of co-cross-linking appeared to be specific for
CD45, because co-cross-linking of FccRIIIb with another surface
molecule, MHC class I, of these cells [by cross-linking bio-
tinylated CLBFcgran 1 F(ab«)
#
and biotinylated W6}32 F(ab«)
#
with streptavidin] did not affect the Ca#+ response caused by
FccRIIIb cross-linking (results not shown). The Ca#+ response
induced by heterotypic cross-linking of both FccRIIa and
FccRIIIb was inhibited by co-cross-linking of CD45, but to a
lesser extent than that induced by FccR cross-linking alone
(Table 1).
Additional experiments were performed with a bsAb, able to
bind to both FccRIII and CD45. Treatment of neutrophils with
the bsAb FccRIII ¬ CD45 followed by cross-linking with GAM
F(ab«)
#
induced only a slight increase in [Ca#+]
i
, which was 10%
of the control response observed after cross-linking of anti-
FccRIII Fab with GAM F(ab«)
#
(Table 1). Co-cross-linking of
CD45 together with anti-FccRIIIb Fab fragments also abolished
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Figure 5 Effect of co-cross-linking of CD45 with FccRs on (A) tyrosine
phosphorylation and (B) translocation of PtdIns 3-kinase to the membrane
Neutrophils were pretreated with biotinylated anti-FccR Fab (lanes 1 and 3, lanes are numbered
from the left) or biotinylated CD45 F(ab«)2 and biotinylated anti-FccR Fab (lanes 2 and 4).
Samples were removed 10 s after cross-linking with streptavidin (10 lg/ml). As control, only
cross-linker was added (lane R). Western blotting was performed (A) with anti-phosphotyrosine
(PY) on neutrophil lysates or (B) with rabbit antiserum directed against the p85 subunit of
PtdIns 3-kinase (anti-p85) in membrane fractions of neutrophils. Similar results were obtained
in three experiments.
Figure 6 Effect of co-cross-linking of CD45 with FccRIIIb on the FccRIIIb-
induced release of b-hexosaminidase
Neutrophils were preincubated without (E) or with (D) biotinylated CD45 F(ab«)2 and then
with biotinylated anti-FccRIII Fab fragments. After washing the cells, streptavidin (10 lg/ml)
was used to cross-link bound antibodies. Results shown are the means³S.E.M. of three
experiments. *Significantly different from control (P ! 0.05).
the Ca#+ response in these experiments (Table 1). The control
response was lower than in the other experiments depicted in
Table 1, because the anti-FccRIII Fab fragments were cross-
linked with GAM F(ab«)
#
, which gave consistently lower re-
sponses than with biotin–streptavidin.
We next investigated the effect of CD45 co-cross-linking on
protein tyrosine phosphorylation upon FccR-induced activation.
Treatment of humanneutrophils with biotinylated Fab fragments
of anti-FccRIIa alone did not induce an increase in protein
tyrosine phosphorylation (results not shown), but when this
antibody was cross-linked with streptavidin, a clear increase in
protein tyrosine phosphorylation was induced (Figure 5A).
Streptavidin alone did not increase protein phosphorylation.
After 10 s, the extent of protein tyrosine phosphorylation
decreased again (results not shown). Stimulating neutrophils by
cross-linking of FccRIIIb also induced protein tyrosine phos-
phorylation, with some differences in the pattern when compared
with FccRIIIb cross-linking (Figure 5A). Tyrosine phosph-
orylation under these conditions was maximal 30 s after cross-
linking (results not shown). Co-cross-linking of CD45 in order to
introduce CD45 into the FccR complexes, inhibited both the
FccRIIa-and the FccRIIIb-induced protein tyrosine phosphor-
ylation (Figure 5A). In accordance with the lower efficacy of
CD45 co-cross-linking in inhibiting the Ca#+ response after
heterotypic cross-linking of FccRIIa and FccRIIIb (Table 1),
the effect of co-cross-linking of CD45 on tyrosine phosphor-
ylation proved to be less pronounced than its effect on the
separate FccR responses (results not shown).
The inhibition of tyrosine phosphorylation by co-cross-linking
of FccR with CD45 was then used to investigate the role of
protein tyrosine phosphorylation in the translocation of PtdIns
3-kinase. Both cross-linking of FccRIIa and of FccRIIIb resulted
in translocation of PtdIns 3-kinase to the membrane fraction
(Figure 5B). The translocation after cross-linking of FccRIIIb
was diminished when CD45 was co-cross-linked with FccRIIIb
(Figure 5B), whereas the FccRIIa-induced translocation of
PtdIns 3-kinase was almost completely prevented by co-cross-
linking of CD45 (Figure 5B). The inhibition of PtdIns 3-kinase
translocation upon FccRIIIb ligation by CD45 co-cross-linking
was largely prevented by pretreatment of the cells with the
tyrosine phosphatase inhibitor pervanadate (25 lM) (results not
shown).
Inhibition of FccR-induced degranulation
We also investigated the effect of CD45 and wortmannin on
functional responses of neutrophils induced via FccR cross-
linking. Cross-linking of FccRIIa hardly induced any release of
b-hexosaminidase (results not shown). Cross-linking of FccRIIIb
in cytochalasin B-treated neutrophils evoked within 30 s the
release of b-hexosaminidase (Figure 6), an enzyme present in
azurophilic granules [32], and vitamin B
"#
-binding protein (results
not shown), a marker for specific granules [33]. In the absence of
cytochalasin B, virtually no granule proteins were detected in the
supernatant (results not shown). Upon cross-linking of CD45
into the FccRIIIb complex, the release of b-hexosaminidase was
abolished (Figure 6) at early time-points. At later times there was
some increase in the amount of b-hexosaminidase in the super-
natant, indicating that the process of degranulation was delayed
under these conditions. A similar pattern of inhibition was
observed for the release of vitamin B
"#
-binding protein (results
not shown). In addition, we also found almost complete in-
hibition of both FccRIIIb- and heterotypic FccR-induced release
of b-hexosaminidase by 100 nM wortmannin: a release of 88%
of the total amount of b-hexosaminidase for heterotypic FccR
activation was only 9% in the presence of wortmannin and a
release of 34% of the total amount of b-hexosaminidase for
FccRIIIb activation was only 6% in the presence of wortmannin.
DISCUSSION
The results of this study indicate that FccR-induced Ca#+
signalling in human neutrophils involves the activation of PtdIns
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3-kinase at a step prior to the generation of Ins(1,4,5)P
$
. The
evidence for this notion comes from two directions. Firstly, we
observed inhibition of Ins(1,4,5)P
$
production, Ca#+ mobilization
and influx after heterotypic FccR cross-linking by wortmannin,
an inhibitor of PtdIns 3-kinase [15,18], with an IC
&!
value of
about 25 nM. This concentration is somewhat higher than the
concentration of wortmannin required to inhibit the purified
PtdIns 3-kinase [34], but similar to the wortmannin concentration
required for treatment of intact cells to inhibit PtdIns 3-kinase
activity recovered in the membrane fraction after FccR cross-
linking (results not shown). In addition, another specific PtdIns
3-kinase inhibitor, LY 294002, also inhibited the accumulation
of Ins(1,4,5)P
$
upon heterotypic FccR cross-linking with an IC
&!
of approximately 1.5 lM, which is comparable with an IC
&!
of
2.5 lM to inhibit fMLP-induced superoxide production in neut-
rophils [35] and a IC
&!
of 1.4 lM against purified PtdIns 3-kinase
[30]. PtdIns 4-kinase, the enzyme involved in the generation of
PtdIns(4,5)P
#
, has been reported not to be inhibited by treatment
of intact cells with wortmannin at concentrations up to 300 nM
[36] or by LY 294002 [30], suggesting that the inhibition of the
Ins(1,4,5)P
$
accumulation by these inhibitors was not due to an
inhibition of PtdIns 4-kinase. It should also be noted that, in
neutrophils, wortmannin was without effect on fMLP-induced
Ins(1,4,5)P
$
generation (Figure 2B), making an effect on PtdIns
metabolism as an alternative explanation highly unlikely.
A second observation indicating the involvement of PtdIns 3-
kinase in FccR signalling in human neutrophils is the very early
activation of this enzyme. When suboptimal cross-linking of
FccR was induced, translocation of PtdIns 3-kinase occurred
before the increase in Ins(1,4,5)P
$
(Figures 2A and 3). An
increase in PtdIns 3-kinase activity in the membrane was observed
also very soon after activation (Figure 4), indicating that, in
addition to the presence of the p85 subunit of PtdIns 3-kinase,
p110 (the catalytic subunit) translocates after FccR cross-linking.
In human neutrophils, there is a suggestion of an alternative
PtdIns 3-kinase activity [37]. This enzyme is activated via G-
proteins and also inhibited by wortmannin. Our observations,
indicating abolishment of both the FccR-induced protein tyro-
sine phosphorylation and the translocation of PtdIns 3-kinase by
co-cross-linking the tyrosine phosphatase CD45 into the FccR
complexes, suggest a role for the classical PtdIns 3-kinase,
although the involvement of the alternative PtdIns 3-kinase
cannot be excluded.
The reason for investigating the effect of CD45 co-cross-
linking was primarily to manipulate intracellular levels of protein
tyrosine phosphorylation. For this purpose, other studies have
employed various synthetic or natural compounds interfering
with tyrosine kinase activities. In some preliminary experiments
we found that most commonly used inhibitors (genistein, herb-
imycin A) were not very effective in preventing FccR-mediated
tyrosine phosphorylation at non-cytotoxic doses. Co-cross-link-
ing of CD45 proved to be most effective in this respect but the
number of CD45 molecules expressed on the surface might be a
limiting factor. This could explain the observation that FccRIIa-
mediated activation is more susceptible to co-cross-linking of
CD45 when compared with FccRIIIb-mediated activation, be-
cause FccRIIIb expression is ten times higher than that of
FccRIIa on human neutrophils [38].
The complete inhibition of FccR-induced enzyme release by
wortmannin and the partial inhibition by CD45 co-cross-lnking
(Figure 6) indicates a role for PtdIns 3-kinase in FccR-induced
degranulation. Most probably, this inhibition is due to the
concomitant inhibition of the Ca#+ response under these cond-
itions. Increased [Ca#+]
i
is required to elicit a degranulation
response in human neutrophils [39,40].
At this point in time, it is difficult to speculate on the exact role
of PtdIns 3-kinase in early signal transduction upon FccR cross-
linking. There are some proposals in the literature for a role for
the cytoskeleton in FccR-mediated Ca#+ mobilization [41,42].
The enzyme PtdIns 3-kinase may be involved here, because it has
been suggested that this enzyme can regulate cytoskeletal re-
organization [43,44]. Recently, Rameh et al. [45] reported the
ability of PtdIns(3,4,5)P
$
, one of the products of PtdIns 3-kinase
activity, to bind to SH2 domains, including to those of the p85
subunit of PtdIns 3-kinase itself. Our results indicate that
PtdIns(3,4,5)P
$
does not play a role in the recruitment of PtdIns
3-kinase to the membrane, because this translocation proved to
be insensitive to wortmannin (results not shown). However, it is
conceivable that the generation of PtdIns(3,4,5)P
$
does play an
instrumental role in the recruitment to the plasma membrane of
phospholipase Cc2, which is probably involved in the FccR-
induced formation of Ins(1,4,5)P
$
[46].
This study was supported by Grant 900-512-092 from the Netherlands Organization
for Scientific Research (NWO). We thank Lily Kannegieter for purification of the
bispecific antibody. We thank Dr M. Thelen for the gift of anti-p85 antiserum and for
stimulating discussions.
REFERENCES
1 Vossebeld, P. J. M., Kessler, J., Von dem Borne, A. E. G. K., Roos, D. and
Verhoeven, A. J. (1995) J. Biol. Chem. 270, 10671–10679
2 Reth, M. (1989) Nature (London) 338, 383–384
3 Odin, J. A., Edberg, J. C., Painter, C. J., Kimberly, R. P. and Unkeless, J. C. (1991)
Science 254, 1785–1788
4 Van den Herik-Oudijk, I. E., Capel, P. J. A., Van der Bruggen, T. and Van de Winkel,
J. G. J. (1995) Blood 85, 2202–2211
5 Keegan, A. D. and Paul, W. E. (1992) Immunol. Today 13, 63–68
6 Hamada, F., Aoki, M., Akiyama, T. and Toyoshima, K. (1993) Proc. Natl. Acad. Sci.
U.S.A. 90, 6305–6309
7 Stefanova, I., Horejsi, V., Ansotegui, I. J., Knapp, W. and Stockinger, H. (1991)
Science 254, 1016–1019
8 Shenoy-Scaria, A. M., Timson Gauen, L. K., Kwong, J., Shaw, A. S. and Lublin, D. M.
(1993) Mol. Cell. Biol. 13, 6385–6392
9 Kaplan, D. R., Whitman, M., Schaffhausen, B., Pallas, D. C., White, M., Cantley, L.
and Roberts, T. M. (1987) Cell 50, 1021–1029
10 Courtneidge, S. A. and Heber, A. (1987) Cell 50, 1031–1037
11 Toker, A., Meyer, M., Reddy, K. K., Falck, J. R., Aneja, R., Aneja, S., Parra, A.,
Burns, D. J., Ballas, L. M. and Cantley, L. C. (1994) J. Biol. Chem. 269,
32358–32367
12 Carpenter, C. L., Duckworth, B. C., Auger, K. R., Cohen, B., Schaffhausen, B. S. and
Cantley, L. C. (1990) J. Biol. Chem. 265, 19704–19711
13 Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R.
and Soltoff, S. (1991) Cell 64, 281–302
14 Exley, M., Varticovski, L., Peter, M., Sancho, J. and Terhorst, C. (1994) J. Biol.
Chem. 269, 15140–15146
15 Okada, T., Sakuma, L., Fukui, Y., Hazeki, O. and Ui, M. (1994) J. Biol. Chem. 269,
3563–3567
16 Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O. and Ui, M. (1994) J. Biol. Chem.
269, 3568–3573
17 Thelen, M., Wymann, M. P. and Langen, H. (1994) Proc. Natl. Acad. Sci. U.S.A. 91,
4960–4964
18 Ui, M., Okada, T., Hazeki, K. and Hazeki, O. (1995) Trends Biochem. Sci. 20,
303–307
19 Ninomiya, N., Hazeki, K., Fukui, Y., Seya, T., Okada, T., Hazeki, O. and Ui, M. (1994)
J. Biol. Chem. 269, 22732–22737
20 Tonks, N. K., Charbonneau, H., Diltz, C. D., Fischer, E. H. and Walsh, K. A. (1988)
Biochemistry 27, 8695–8701
21 Fleit, H. B., Wright, S. D. and Unkeless, J. C. (1982) Proc. Natl. Acad. Sci. U.S.A.
79, 3275–3279
22 Werner, G., Von dem Borne, A. E. G. Kr., Bos, M. J. E., Tromp, J. F., Van der Plas-
Van Dalen, C. M., Visser, F. J., Engelfriet, C. P. and Tetteroo, P. A. T. (1985) in
Leukocyte Typing II (Reinherz, E. L., Haynes, B. F., Nadler, L. M. and Bernstein, I. D.,
eds.), pp. 109–121, Springer Verlag, New York
94 P. J. M. Vossebeld and others
23 Rosenfeld, S. I., Looney, R. J., Leddy, J. P., Phipps, D. C., Abraham, G. N. and
Anderson, C. L. (1985) J. Clin. Invest. 76, 2317–2322
24 Ory, P. A., Clark, M. R., Talhouk, A. S. and Goldstein, I. M. (1991) Blood 77,
2682–2687
25 Verhoeven, A. J., Leusen, J. H. W., Kessels, G. C. R., Hilarius, P. M., De Bont, D. B.
and Liskamp, R. M. (1993) J. Biol. Chem. 268, 18593–18598
26 Dewald, B., Thelen, M. and Baggiolini, M. (1988) J. Biol. Chem. 263, 16179–16184
27 Putney, J. W. (1990) Cell Calcium 11, 611–624
28 Demaurex, N., Monod, A., Lew, D. P. and Krause, K. H. (1994) Biochem. J. 297,
595–601
29 Della Bianca, V., Grzeskowiak, M., Dusi, S. and Rossi, F. (1993) Biochem. Biophys.
Res. Commun. 198, 1233–1239
30 Vlahos, C. J., Matter, W. F., Hui, K. Y. and Brown, R. F. (1994) J. Biol. Chem. 269,
5241–5248
31 Hoffmeyer, F., Witte, K., Gebhardt, U. and Schmidt, R. E. (1995) J. Immunol. 155,
4016–4023
32 Bretz, U. and Baggiolini, M. (1974) J. Cell Biol. 63, 251–269
33 Kane, S. P. and Peters, T. J. (1975) Clin. Sci. Mol. Med. 49, 171–182
34 Yano, H., Nakanishi, S., Kimura, K., Hanai, N., Saitoh, Y., Fukui, Y., Nonomura, Y.
and Matsuda, Y. (1993) J. Biol. Chem. 268, 25846–25856
35 Vlahos, C. J., Matter, W. F., Brown, R. F., Traynor Kaplan, A. E., Heyworth, P. G.,
Received 10 January 1996/29 October 1996 ; accepted 13 November 1996
Prossnitz, E. R., Ye, R. D., Marder, P., Schelm, J. A., Rothfuss, K. J. et al. (1995)
J. Immunol. 154, 2413–2422
36 Nakanishi, S., Catt, K. J. and Balla, T. (1995) Proc. Natl. Acad. Sci. U.S.A. 92,
5317–5321
37 Stephens, L., Smrcka, A., Cooke, F. T., Jackson, T. R., Sternweis, P. C. and Hawkins,
P. T. (1994) Cell 77, 83–93
38 Huizinga, T. W., Kerst, M., Nuyens, J. H., Vlug, A., Von dem Borne, A. E., Roos, D.
and Tetteroo, P. A. (1989) J. Immunol. 142, 2359–2364
39 Lew, P. D., Wollheim, C. B., Waldvogel, F. A. and Pozzan, T. (1984) J. Cell Biol. 99,
1212–1220
40 Niessen, H. W. and Verhoeven, A. J. (1992) Cell. Signalling 4, 501–509
41 Rosales, C., Jones, S. L., McCourt, D. and Brown, E. J. (1994) Proc. Natl. Acad. Sci.
U.S.A. 91, 3534–3538
42 Greenberg, S. (1995) Trends Cell Biol. 5, 93–99
43 Shibasaki, F., Fukami, K., Fukui, Y. and Takenawa, T. (1994) Biochem. J. 302,
551–557
44 Grondin, P., Plantavid, M., Sultan, C., Breton, M., Mauco, G. and Chap, H. (1991)
J. Biol. Chem. 266, 15705–15709
45 Rameh, L. E., Chen, C. and Cantley, L. C. (1995) Cell 83, 821–830
46 Dusi, S., Donini, M., Della Bianca, V. and Rossi, F. (1994) Biochem. Biophys. Res.
Commun. 201, 1100–1108
